|
1
|
Ostrom QT, Gittleman H, de Blank PM,
Finlay JL, Gurney JG, McKean-Cowdin R, Stearns DS, Wolff JE, Liu M,
Wolinsky Y, et al: American brain tumor association adolescent and
young adult primary brain and central nervous system tumors
diagnosed in the United States in 2008-2012. Neuro Oncol. 18 (Suppl
1):i1–i50. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ostrom QT, Gittleman H, Truitt G, Boscia
A, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical report:
Primary brain and other central nervous system tumors diagnosed in
the United States in 2011-2015. Neuro Oncol. 20 (Supp l4):iv1–iv86.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vadgaonkar R, Epari S, Chinnaswamy G,
Krishnatry R, Tonse R, Gupta T and Jalali R: Distinct demographic
profile and molecular markers of primary CNS tumor in 1873
adolescent and young adult patient population. Childs Nerv Syst.
34:1489–1495. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Husson O, Zebrack B, Block R, Embry L,
Aguilar C, Hayes-Lattin B and Cole S: Personality traits and
health-related quality of life among adolescent and young adult
cancer patients: The role of psychological distress. J Adolesc
Young Adult Oncol. 6:358–362. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chandra V, Das T, Gulati P, Biswas NK,
Rote S, Chatterjee U, Ghosh SN, Deb S, Saha SK, Chowdhury AK, et
al: Hedgehog signaling pathway is active in GBM with GLI1 mRNA
expression showing a single continuous distribution rather than
discrete high/low clusters. PLoS One. 10:e01163902015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Azzi S, Treps L, Leclair HM, Ngo HM,
Harford-Wright E and Gavard J: Desert Hedgehog/Patch2 axis
contributes to vascular permeability and angiogenesis in
glioblastoma. Front Pharmacol. 6:2812015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Takezaki T, Hide T, Takanaga H, Nakamura
H, Kuratsu J and Kondo T: Essential role of the Hedgehog signaling
pathway in human glioma-initiating cells. Cancer Sci.
102:1306–1312. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chang J, Guo C, Li J, Liang Z, Wang Y, Yu
A, Liu R, Guo Y, Chen J and Huang S: EN1 regulates cell growth and
proliferation in human glioma cells via Hedgehog signaling. Int J
Mol Sci. 23:11232022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chang L, Zhang P, Zhao D, Liu H, Wang Q,
Li C, Du W, Liu X, Zhang H, Zhang Z and Jiang C: The Hedgehog
antagonist HHIP as a favorable prognosticator in glioblastoma.
Tumour Biol. 37:3979–3986. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Infante P, Mori M, Alfonsi R, Ghirga F,
Aiello F, Toscano S, Ingallina C, Siler M, Cucchi D, Po A, et al:
Gli1/DNA interaction is a druggable target for Hedgehog-dependent
tumors. EMBO J. 34:200–217. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 World Health Organization
classification of tumors of the central nervous system: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cancer Genome Atlas Research Network, .
Comprehensive genomic characterization defines human glioblastoma
genes and core pathways. Nature. 455:1061–1068. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Parsons DW, Jones S, Zhang X, Lin JC,
Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et
al: An integrated genomic analysis of human glioblastoma
multiforme. Science. 321:1807–1812. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ceccarelli M, Barthel FP, Malta TM,
Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh
A, Pagnotta SM, et al: Molecular profiling reveals biologically
discrete subsets and pathways of progression in diffuse glioma.
Cell. 164:550–563. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Q, Hu B, Hu X, Kim H, Squatrito M,
Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, et al: Tumor
evolution of glioma-intrinsic gene expression subtypes associates
with immunological changes in the microenvironment. Cancer Cell.
32:42–56.e6. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sturm D, Bender S, Jones DT, Lichter P,
Grill J, Becher O, Hawkins C, Majewski J, Jones C, Costello JF, et
al: Paediatric and adult glioblastoma: Multiform (epi)genomic
culprits emerge. Nat Rev Cancer. 14:92–107. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Capper D, Jones DTW, Sill M, Hovestadt V,
Schrimpf D, Sturm D, Koelsche C, Sahm F, Chavez L, Reuss DE, et al:
DNA methylation-based classification of central nervous system
tumours. Nature. 555:469–474. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Torrisi F, Alberghina C, D'Aprile S,
Pavone AM, Longhitano L, Giallongo S, Tibullo D, Di Rosa M, Zappalà
A, Cammarata FP, et al: The hallmarks of glioblastoma:
Heterogeneity, intercellular crosstalk and molecular signature of
invasiveness and progression. Biomedicines. 10:8062022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ostrom QT, Cioffi G, Gittleman H, Patil N,
Waite K, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical
report: Primary brain and other central nervous system tumors
diagnosed in the United States in 2012-2016. Neuro Oncol 21 (Suppl
5):v1-v100; 2019, View Article : Google Scholar
|
|
20
|
Roa W, Brasher PM, Bauman G, Anthes M,
Bruera E, Chan A, Fisher B, Fulton D, Gulavita S, Hao C, et al:
Abbreviated course of radiation therapy in older patients with
glioblastoma multiforme: A prospective randomized clinical trial. J
Clin Oncol. 22:1583–1588. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Suchorska B, Weller M, Tabatabai G, Senft
C, Hau P, Sabel MC, Herrlinger U, Ketter R, Schlegel U, Marosi C,
et al: Complete resection of contrast-enhancing tumor volume is
associated with improved survival in recurrent glioblastoma-results
from the DIRECTOR trial. Neuro Oncol. 18:549–556. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Stupp R, Wong ET, Kanner AA, Steinberg D,
Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F,
Dbalý V, et al: NovoTTF-100A versus physician's choice chemotherapy
in recurrent glioblastoma: A randomised phase III trial of a novel
treatment modality. Eur J Cancer. 48:2192–2202. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Höing S, Yeh TY, Baumann M, Martinez NE,
Habenberger P, Kremer L, Drexler HCA, Küchler P, Reinhardt P,
Choidas A, et al: Dynarrestin, a novel inhibitor of cytoplasmic
dynein. Cell Chem Biol. 25:357–369.e6. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rocha CRR, Reily Rocha A, Molina Silva M,
Rodrigues Gomes L, Teatin Latancia M, Andrade Tomaz M, de Souza I,
Karolynne Seregni Monteiro L and Menck CFM: Revealing temozolomide
resistance mechanisms via genome-wide CRISPR libraries. Cells.
9:25732020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ebrahimi A, Larijani L, Moradi A and
Ebrahimi MR: Hedgehog signalling pathway: Carcinogenesis and
targeted therapy. Iran J Cancer Prev. 6:36–43. 2013.PubMed/NCBI
|
|
26
|
Jin X, Jeon HM, Jin X, Kim EJ, Yin J, Jeon
HY, Sohn YW, Oh SY, Kim JK, Kim SH, et al: The ID1-CULLIN3 axis
regulates intracellular SHH and WNT signaling in glioblastoma stem
cells. Cell Rep. 16:1629–1641. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huynh DL, Koh H, Chandimali N, Zhang JJ,
Kim N, Kang TY, Ghosh M, Gera M, Park YH, Kwon T and Jeong DK:
BRM270 inhibits the proliferation of CD44 positive pancreatic
ductal adenocarcinoma cells via downregulation of sonic Hedgehog
signaling. Evid Based Complement Alternat Med. 2019:86204692019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Marigo V and Tabin CJ: Regulation of
patched by sonic Hedgehog in the developing neural tube. Proc Natl
Acad Sci USA. 93:9346–9351. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Plotnikova OV, Golemis EA and Pugacheva
EN: Cell cycle-dependent ciliogenesis and cancer. Cancer Res.
68:2058–2061. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mastronardi FG, Dimitroulakos J,
Kamel-Reid S and Manoukian AS: Co-localization of patched and
activated sonic Hedgehog to lysosomes in neurons. Neuroreport.
11:581–585. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rubin LL and de Sauvage FJ: Targeting the
Hedgehog pathway in cancer. Nat Rev Drug Discov. 5:1026–1033. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Alexandre C, Jacinto A and Ingham PW:
Transcriptional activation of Hedgehog target genes in Drosophila
is mediated directly by the cubitus interruptus protein, a member
of the GLI family of zinc finger DNA-binding proteins. Genes Dev.
10:2003–2013. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pan Y, Bai CB, Joyner AL and Wang B: Sonic
Hedgehog signaling regulates Gli2 transcriptional activity by
suppressing its processing and degradation. Mol Cell Biol.
26:3365–3377. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang B, Fallon JF and Beachy PA:
Hedgehog-regulated processing of Gli3 produces an
anterior/posterior repressor gradient in the developing vertebrate
limb. Cell. 100:423–434. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Niewiadomski P, Kong JH, Ahrends R, Ma Y,
Humke EW, Khan S, Teruel MN, Novitch BG and Rohatgi R: Gli protein
activity is controlled by multisite phosphorylation in vertebrate
Hedgehog signaling. Cell Rep. 6:168–181. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gonnissen A, Isebaert S and Haustermans K:
Targeting the Hedgehog signaling pathway in cancer: Beyond
smoothened. Oncotarget. 6:13899–13913. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Skoda AM, Simovic D, Karin V, Kardum V,
Vranic S and Serman L: The role of the Hedgehog signaling pathway
in cancer: A comprehensive review. Bosn J Basic Med Sci. 18:8–20.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sabol M, Trnski D, Musani V, Ozretić P and
Levanat S: Role of GLI transcription factors in pathogenesis and
their potential as new therapeutic targets. Int J Mol Sci.
19:25622018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Endoh-Yamagami S, Evangelista M, Wilson D,
Wen X, Theunissen JW, Phamluong K, Davis M, Scales SJ, Solloway MJ,
de Sauvage FJ and Peterson AS: The mammalian Cos2 homolog Kif7
plays an essential role in modulating Hh signal transduction during
development. Curr Biol. 19:1320–1326. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Denef N, Neubüser D, Perez L and Cohen SM:
Hedgehog induces opposite changes in turnover and subcellular
localization of patched and smoothened. Cell. 102:521–531. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tschaikner P, Enzler F, Torres-Quesada O,
Aanstad P and Stefan E: Hedgehog and Gpr161: Regulating cAMP
signaling in the primary cilium. Cells. 9:1182020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Price MA and Kalderon D: Proteolysis of
the Hedgehog signaling effector cubitus interruptus requires
phosphorylation by glycogen synthase kinase 3 and casein kinase 1.
Cell. 108:823–835. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Méthot N and Basler K: Suppressor of fused
opposes Hedgehog signal transduction by impeding nuclear
accumulation of the activator form of cubitus interruptus.
Development. 127:4001–4010. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Brennan D, Chen X, Cheng L, Mahoney M and
Riobo NA: Noncanonical Hedgehog signaling. Vitam Horm. 88:55–72.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Robbins DJ, Fei DL and Riobo NA: The
Hedgehog signal transduction network. Sci Signal. 5:re62012.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Awasthi A, Woolley AG, Lecomte FJ, Hung N,
Baguley BC, Wilbanks SM, Jeffs AR and Tyndall JD: Variable
expression of GLIPR1 correlates with invasive potential in melanoma
cells. Front Oncol. 3:2252013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang K, Pan L, Che X, Cui D and Li C:
Sonic Hedgehog/GLI1 signaling pathway inhibition restricts cell
migration and invasion in human gliomas. Neurol Res. 32:975–980.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lo HW, Zhu H, Cao X, Aldrich A and
Ali-Osman F: A novel splice variant of GLI1 that promotes
glioblastoma cell migration and invasion. Cancer Res. 69:6790–6798.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Reifenberger J, Wolter M, Weber RG,
Megahed M, Ruzicka T, Lichter P and Reifenberger G: Missense
mutations in SMOH in sporadic basal cell carcinomas of the skin and
primitive neuroectodermal tumors of the central nervous system.
Cancer Res. 58:1798–1803. 1998.PubMed/NCBI
|
|
50
|
Lee Y, Miller HL, Jensen P, Hernan R,
Connelly M, Wetmore C, Zindy F, Roussel MF, Curran T, Gilbertson RJ
and McKinnon PJ: A molecular fingerprint for medulloblastoma.
Cancer Res. 63:5428–5437. 2003.PubMed/NCBI
|
|
51
|
Lim CB, Prêle CM, Cheah HM, Cheng YY,
Klebe S, Reid G, Watkins DN, Baltic S, Thompson PJ and Mutsaers SE:
Mutational analysis of Hedgehog signaling pathway genes in human
malignant mesothelioma. PLoS One. 8:e666852013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Berman DM, Karhadkar SS, Maitra A, Montes
De Oca R, Gerstenblith MR, Briggs K, Parker AR, Shimada Y, Eshleman
JR, Watkins DN and Beachy PA: Widespread requirement for Hedgehog
ligand stimulation in growth of digestive tract tumours. Nature.
425:846–851. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Noman AS, Uddin M, Rahman MZ, Nayeem MJ,
Alam SS, Khatun Z, Wahiduzzaman M, Sultana A, Rahman ML, Ali MY, et
al: Overexpression of sonic Hedgehog in the triple negative breast
cancer: Clinicopathological characteristics of high burden breast
cancer patients from Bangladesh. Sci Rep. 6:188302016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Watkins DN, Berman DM, Burkholder SG, Wang
B, Beachy PA and Baylin SB: Hedgehog signalling within airway
epithelial progenitors and in small-cell lung cancer. Nature.
422:313–317. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Riobo-Del Galdo NA, Lara Montero Á and
Wertheimer EV: Role of Hedgehog signaling in breast cancer:
Pathogenesis and therapeutics. Cells. 8:3752019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Hanahan D and Coussens LM: Accessories to
the crime: Functions of cells recruited to the tumor
microenvironment. Cancer Cell. 21:309–322. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Petersen OW, Rønnov-Jessen L, Howlett AR
and Bissell MJ: Interaction with basement membrane serves to
rapidly distinguish growth and differentiation pattern of normal
and malignant human breast epithelial cells. Proc Natl Acad Sci
USA. 89:9064–9068. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Martinez-Outschoorn U, Sotgia F and
Lisanti MP: Tumor microenvironment and metabolic synergy in breast
cancers: Critical importance of mitochondrial fuels and function.
Semin Oncol. 41:195–216. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Martinez-Outschoorn UE, Lin Z, Ko YH,
Goldberg AF, Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell
A, Sotgia F and Lisanti MP: Understanding the metabolic basis of
drug resistance: Therapeutic induction of the Warburg effect kills
cancer cells. Cell Cycle. 10:2521–2528. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Chang L, Zhao D, Liu HB, Wang QS, Zhang P,
Li CL, Du WZ, Wang HJ, Liu X, Zhang ZR and Jiang CL: Activation of
sonic Hedgehog signaling enhances cell migration and invasion by
induction of matrix metalloproteinase-2 and −9 via the
phosphoinositide-3 kinase/AKT signaling pathway in glioblastoma.
Mol Med Rep. 12:6702–6710. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Torrisi F, Alberghina C, Lo Furno D,
Zappalà A, Valable S, Li Volti G, Tibullo D, Vicario N and Parenti
R: Connexin 43 and Sonic Hedgehog pathway interplay in glioblastoma
cell proliferation and migration. Biology (Basel).
10:7672021.PubMed/NCBI
|
|
62
|
Cherepanov SA, Cherepanova KI, Grinenko
NF, Antonova OM and Chekhonin VP: Effect of Hedgehog signaling
pathway activation on proliferation of high-grade gliomas. Bull Exp
Biol Med. 161:674–678. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Rowitch DH, S-Jacques B, Lee SM, Flax JD,
Snyder EY and McMahon AP: Sonic Hedgehog regulates proliferation
and inhibits differentiation of CNS precursor cells. J Neurosci.
19:8954–8965. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Jiang K, Wang YP, Wang XD, Hui XB, Ding
LS, Liu J and Liu D: Fms related tyrosine kinase 1 (Flt1) functions
as an oncogene and regulates glioblastoma cell metastasis by
regulating sonic Hedgehog signaling. Am J Cancer Res. 7:1164–1176.
2017.PubMed/NCBI
|
|
65
|
Hamerlik P, Lathia JD, Rasmussen R, Wu Q,
Bartkova J, Lee M, Moudry P, Bartek J Jr, Fischer W, Lukas J, et
al: Autocrine VEGF-VEGFR2-neuropilin-1 signaling promotes glioma
stem-like cell viability and tumor growth. J Exp Med. 209:507–520.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Kloepper J, Riedemann L, Amoozgar Z, Seano
G, Susek K, Yu V, Dalvie N, Amelung RL, Datta M, Song JW, et al:
Ang-2/VEGF bispecific antibody reprograms macrophages and resident
microglia to anti-tumor phenotype and prolongs glioblastoma
survival. Proc Natl Acad Sci USA. 113:4476–4481. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Chen L, Wang L, Qin J and Wei DS: CtBP2
interacts with ZBTB18 to promote malignancy of glioblastoma. Life
Sci. 262:1184772020. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Bensalma S, Turpault S, Balandre AC, De
Boisvilliers M, Gaillard A, Chadéneau C and Muller JM: PKA at a
cross-road of signaling pathways involved in the regulation of
glioblastoma migration and invasion by the neuropeptides VIP and
PACAP. Cancers (Basel). 11:1232019. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Henao-Restrepo J, Caro-Urrego YA,
Barrera-Arenas LM, Arango-Viana JC and Bermudez-Munoz M: Expression
of activator proteins of SHH/GLI and PI3K/Akt/mTORC1 signaling
pathways in human gliomas is associated with high grade tumors. Exp
Mol Pathol. 122:1046732021. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Kinzler KW, Bigner SH, Bigner DD, Trent
JM, Law ML, O'Brien SJ, Wong J and Vogelstein B: Identification of
an amplified, highly expressed gene in a human glioma. Science.
236:70–73. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Bigner SH, Wong AJ, Mark J, Muhlbaier LH,
Kinzler KW, Vogelstein B and Bigner DD: Relationship between gene
amplification and chromosomal deviations in malignant human
gliomas. Cancer Genet Cytogenet. 29:165–170. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
ten Haaf A, Bektas N, von Serenyi S, Losen
I, Arweiler EC, Hartmann A, Knuchel R and Dahl E: Expression of the
glioma-associated oncogene homolog (GLI) 1 in human breast cancer
is associated with unfavourable overall survival. BMC Cancer.
9:2982009. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Zhou A, Lin K, Zhang S, Ma L, Xue J,
Morris SA, Aldape KD and Huang S: Gli1-induced deubiquitinase USP48
aids glioblastoma tumorigenesis by stabilizing Gli1. EMBO Rep.
18:1318–1330. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Kim Y, Do IG, Hong M and Suh YL: Negative
prognostic effect of low nuclear GLI1 expression in glioblastomas.
J Neurooncol. 133:69–76. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Xue J, Zhou A, Tan C, Wu Y, Lee HT, Li W,
Xie K and Huang S: Forkhead box M1 is essential for nuclear
localization of glioma-associated oncogene homolog 1 in
glioblastoma multiforme cells by promoting importin-7 expression. J
Biol Chem. 290:18662–18670. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Zhu H, Carpenter RL, Han W and Lo HW: The
GLI1 splice variant TGLI1 promotes glioblastoma angiogenesis and
growth. Cancer Lett. 343:51–61. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Zhang Z, Zheng X, Luan Y and Liu Y, Li X,
Liu C, Lu H, Chen X and Liu Y: Activity of metabotropic glutamate
receptor 4 suppresses proliferation and promotes apoptosis with
inhibition of Gli-1 in human glioblastoma cells. Front Neurosci.
12:3202018. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Sargazi ML, Juybari KB, Tarzi ME,
Amirkhosravi A, Nematollahi MH, Mirzamohammdi S, Mehrbani M and
Mehrabani M and Mehrabani M: Naringenin attenuates cell viability
and migration of C6 glioblastoma cell line: A possible role of
Hedgehog signaling pathway. Mol Biol Rep. 48:6413–6421. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Chantaravisoot N, Wongkongkathep P, Loo
AJ, Mischel SP and Tamanoi F: Significance of filamin A in mTORC2
function in glioblastoma. Mol Cancer. 14:e1272015. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Maiti S, Mondal S, Satyavarapu EM and
Mandal C: mTORC2 regulates Hedgehog pathway activity by promoting
stability to Gli2 protein and its nuclear translocation. Cell Death
Dis. 8:e29262017. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Tanigawa S, Fujita M, Moyama C, Ando S, Ii
H, Kojima Y, Fujishita T, Aoki M, Takeuchi H, Yamanaka T, et al:
Inhibition of Gli2 suppresses tumorigenicity in glioblastoma stem
cells derived from a de novo murine brain cancer model. Cancer Gene
Ther. 28:1339–1352. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Zaphiropoulos PG, Undén AB, Rahnama F,
Hollingsworth RE and Toftgård R: PTCH2, a novel human patched gene,
undergoing alternative splicing and up-regulated in basal cell
carcinomas. Cancer Res. 59:787–792. 1999.PubMed/NCBI
|
|
83
|
Larsson NG, Wang J, Wilhelmsson H, Oldfors
A, Rustin P, Lewandoski M, Barsh GS and Clayton DA: Mitochondrial
transcription factor A is necessary for mtDNA maintenance and
embryogenesis in mice. Nat Genet. 18:231–236. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Rudin CM, Hann CL, Laterra J, Yauch RL,
Callahan CA, Fu L, Holcomb T, Stinson J, Gould SE, Coleman B, et
al: Treatment of medulloblastoma with Hedgehog pathway inhibitor
GDC-0449. N Engl J Med. 361:1173–1178. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Scales SJ and de Sauvage FJ: Mechanisms of
Hedgehog pathway activation in cancer and implications for therapy.
Trends Pharmacol Sci. 30:303–312. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Marjanovic Vicentic J, Drakulic D, Garcia
I, Vukovic V, Aldaz P, Puskas N, Nikolic I, Tasic G, Raicevic S,
Garros-Regulez L, et al: SOX3 can promote the malignant behavior of
glioblastoma cells. Cell Oncol (Dordr). 42:41–54. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Saito A, Kanemoto S, Zhang Y, Asada R,
Hino K and Imaizumi K: Chondrocyte proliferation regulated by
secreted luminal domain of ER stress transducer BBF2H7/CREB3L2. Mol
Cell. 53:127–139. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Iwamoto H, Matsuhisa K, Saito A, Kanemoto
S, Asada R, Hino K, Takai T, Cui M, Cui X, Kaneko M, et al:
Promotion of cancer cell proliferation by cleaved and secreted
luminal domains of ER stress transducer BBF2H7. PLoS One.
10:e01259822015. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Guen VJ, Chavarria TE, Kröger C, Ye X,
Weinberg RA and Lees JA: EMT programs promote basal mammary stem
cell and tumor-initiating cell stemness by inducing primary
ciliogenesis and Hedgehog signaling. Proc Natl Acad Sci USA.
114:E10532–E10539. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Brandner S: Nanog, Gli, and p53: A new
network of stemness in development and cancer. EMBO J.
29:2475–2476. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Rich JN and Eyler CE: Cancer stem cells in
brain tumor biology. Cold Spring Harb Symp Quant Biol. 73:411–420.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
de Groot JF, Fuller G, Kumar AJ, Piao Y,
Eterovic K, Ji Y and Conrad CA: Tumor invasion after treatment of
glioblastoma with bevacizumab: Radiographic and pathologic
correlation in humans and mice. Neuro Oncol. 12:233–242. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Han B, Wang R, Chen Y, Meng X, Wu P, Li Z,
Duan C, Li Q, Li Y, Zhao S, et al: QKI deficiency maintains glioma
stem cell stemness by activating the SHH/GLI1 signaling pathway.
Cell Oncol (Dordr). 42:801–813. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Yuan Y, Zhang M, Yan G, Ma Q, Yan Z, Wang
L, Yang K and Guo D: Nanog promotes stem-like traits of
glioblastoma cells. Front Biosci (Landmark Ed). 26:552–565. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Silvestri I, Testa F, Zappasodi R, Cairo
CW, Zhang Y, Lupo B, Galli R, Di Nicola M, Venerando B and Tringali
C: Sialidase NEU4 is involved in glioblastoma stem cell survival.
Cell Death Dis. 5:e13812014. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Kundu S, Nandhu MS, Longo SL, Longo JA,
Rai S, Chin LS, Richardson TE and Viapiano MS: The scaffolding
protein DLG5 promotes glioblastoma growth by controlling sonic
Hedgehog signaling in tumor stem cells. Neuro Oncol: noac001.
2022.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Park MG, Seo S, Ham SW, Choi SH and Kim H:
Dihydropyrimidinase-related protein 5 controls glioblastoma stem
cell characteristics as a biomarker of proneural-subtype
glioblastoma stem cells. Oncol Lett. 20:1153–1162. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Mondal S, Bhattacharya K and Mandal C:
Nutritional stress reprograms dedifferention in glioblastoma
multiforme driven by PTEN/Wnt/Hedgehog axis: A stochastic model of
cancer stem cells. Cell Death Discov. 4:1102018. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Yan GN, Yang L, Lv YF, Shi Y, Shen LL, Yao
XH, Guo QN, Zhang P, Cui YH, Zhang X, et al: Endothelial cells
promote stem-like phenotype of glioma cells through activating the
Hedgehog pathway. J Pathol. 234:11–22. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Sekulic A, Migden MR, Oro AE, Dirix L,
Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander
PA, et al: Efficacy and safety of vismodegib in advanced basal-cell
carcinoma. N Engl J Med. 366:2171–2179. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Robinson GW, Orr BA, Wu G, Gururangan S,
Lin T, Qaddoumi I, Packer RJ, Goldman S, Prados MD, Desjardins A,
et al: Vismodegib exerts targeted efficacy against recurrent sonic
Hedgehog-subgroup medulloblastoma: Results from phase II pediatric
brain tumor consortium studies PBTC-025B and PBTC-032. J Clin
Oncol. 33:2646–2654. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Wong R, Turlova E, Feng ZP, Rutka JT and
Sun HS: Activation of TRPM7 by naltriben enhances migration and
invasion of glioblastoma cells. Oncotarget. 8:11239–11248. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Shojaei F, Lee JH, Simmons BH, Wong A,
Esparza CO, Plumlee PA, Feng J, Stewart AE, Hu-Lowe DD and
Christensen JG: HGF/c-Met acts as an alternative angiogenic pathway
in sunitinib-resistant tumors. Cancer Res. 70:10090–10100. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Lu KV, Chang JP, Parachoniak CA, Pandika
MM, Aghi MK, Meyronet D, Isachenko N, Fouse SD, Phillips JJ,
Cheresh DA, et al: VEGF inhibits tumor cell invasion and
mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell.
22:21–35. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Li L and Li W: Epithelial-mesenchymal
transition in human cancer: Comprehensive reprogramming of
metabolism, epigenetics, and differentiation. Pharmacol Ther.
150:33–46. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Chaffer CL, San Juan BP, Lim E and
Weinberg RA: EMT, cell plasticity and metastasis. Cancer Metastasis
Rev. 35:645–654. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Tang H, Massi D, Hemmings BA, Mandalà M,
Hu Z, Wicki A and Xue G: AKT-ions with a TWIST between EMT and MET.
Oncotarget. 7:62767–62777. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Yeung KT and Yang J:
Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol.
11:28–39. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Urdiciain A, Erausquin E, Meléndez B, Rey
JA, Idoate MA and Castresana JS: Tubastatin A, an inhibitor of
HDAC6, enhances temozolomide-induced apoptosis and reverses the
malignant phenotype of glioblastoma cells. Int J Oncol.
54:1797–1808. 2019.PubMed/NCBI
|
|
110
|
Feng X, Yao J, Gao X, Jing Y, Kang T,
Jiang D, Jiang T, Feng J, Zhu Q, Jiang X and Chen J:
Multi-targeting peptide-functionalized nanoparticles recognized
vasculogenic mimicry, tumor neovasculature, and glioma cells for
enhanced anti-glioma therapy. ACS Appl Mater Interfaces.
7:27885–27899. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Kast RE, Skuli N, Karpel-Massler G,
Frosina G, Ryken T and Halatsch ME: Blocking
epithelial-to-mesenchymal transition in glioblastoma with a sextet
of repurposed drugs: The EIS regimen. Oncotarget. 8:60727–60749.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Li M, Zhang J, Zhou H and Xiang R: Primary
cilia-related pathways moderate the development and therapy
resistance of glioblastoma. Front Oncol. 11:7189952021. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Jenks AD, Vyse S, Wong JP, Kostaras E,
Keller D, Burgoyne T, Shoemark A, Tsalikis A, de la Roche M,
Michaelis M, et al: Primary cilia mediate diverse kinase inhibitor
resistance mechanisms in cancer. Cell Rep. 23:3042–3055. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Carpenter RL and Lo HW: Hedgehog pathway
and GLI1 isoforms in human cancer. Discov Med. 13:105–113.
2012.PubMed/NCBI
|
|
115
|
Honorato JR, Hauser-Davis RA, Saggioro EM,
Correia FV, Sales-Junior SF, Soares LOS, Lima LDR, Moura-Neto V,
Lopes GPF and Spohr TCLS: Role of sonic Hedgehog signaling in cell
cycle, oxidative stress, and autophagy of temozolomide resistant
glioblastoma. J Cell Physiol. 235:3798–3814. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Melamed JR, Morgan JT, Ioele SA, Gleghorn
JP, Sims-Mourtada J and Day ES: Investigating the role of
Hedgehog/GLI1 signaling in glioblastoma cell response to
temozolomide. Oncotarget. 9:27000–27015. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Lai IC, Shih PH, Yao CJ, Yeh CT, Wang-Peng
J, Lui TN, Chuang SE, Hu TS, Lai TY and Lai GM: Elimination of
cancer stem-like cells and potentiation of temozolomide sensitivity
by honokiol in glioblastoma multiforme cells. PLoS One.
10:e01148302015. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Sarkaria JN, Kitange GJ, James CD, Plummer
R, Calvert H, Weller M and Wick W: Mechanisms of chemoresistance to
alkylating agents in malignant glioma. Clin Cancer Res.
14:2900–2908. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Munoz JL, Rodriguez-Cruz V, Walker ND,
Greco SJ and Rameshwar P: Temozolomide resistance and tumor
recurrence: Halting the Hedgehog. Cancer Cell Microenviron.
2:e7472015.PubMed/NCBI
|
|
120
|
Hung HC, Liu CC, Chuang JY, Su CL and Gean
PW: Inhibition of sonic Hedgehog signaling suppresses glioma
stem-like cells likely through inducing autophagic cell death.
Front Oncol. 10:12332020. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Chen J, Fu X, Wan Y, Wang Z, Jiang D and
Shi L: miR-125b inhibitor enhance the chemosensitivity of
glioblastoma stem cells to temozolomide by targeting Bak1. Tumour
Biol. 35:6293–6302. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Melamed JR, Ioele SA, Hannum AJ, Ullman VM
and Day ES: Polyethylenimine-spherical nucleic acid nanoparticles
against Gli1 reduce the chemoresistance and stemness of
glioblastoma cells. Mol Pharm. 15:5135–5145. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Ding D, Lim KS and Eberhart CG: Arsenic
trioxide inhibits Hedgehog, notch and stem cell properties in
glioblastoma neurospheres. Acta Neuropathol Commun. 2:312014.
View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Wang J, Huang S, Tian R, Chen J, Gao H,
Xie C, Shan Y, Zhang Z, Gu S and Xu M: The protective autophagy
activated by GANT-61 in MYCN amplified neuroblastoma cells is
mediated by PERK. Oncotarget. 9:14413–14427. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Carballo GB, Ribeiro JH, Lopes GPF, Ferrer
VP, Dezonne RS, Pereira CM and Spohr TCLSE: GANT-61 induces
autophagy and apoptosis in glioblastoma cells despite their
heterogeneity. Cell Mol Neurobiol. 41:1227–1244. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Yin S, Du W, Wang F, Han B, Cui Y, Yang D,
Chen H, Liu D, Liu X, Zhai X and Jiang C: MicroRNA-326 sensitizes
human glioblastoma cells to curcumin via the SHH/GLI1 signaling
pathway. Cancer Biol Ther. 19:260–270. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Ji M, Zhang Z, Lin S, Wang C, Jin J, Xue
N, Xu H and Chen X: The PI3K inhibitor XH30 enhances response to
temozolomide in drug-resistant glioblastoma via the noncanonical
Hedgehog signaling pathway. Front Pharmacol. 12:7492422021.
View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Han L, Tang L, Jiang Z and Jiang Y:
Enhanced radiosensitization of human glioblastoma multiforme cells
with phosphorylated peptides derived from Gli2. Neuropeptides.
70:87–92. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Urdiciain A, Erausquin E, Zelaya MV, Zazpe
I, Lanciego JL, Meléndez B, Rey JA, Idoate MA, Riobo-Del Galdo NA
and Castresana JS: Silencing of histone deacetylase 6 decreases
cellular malignancy and contributes to primary cilium restoration,
epithelial-to-mesenchymal transition reversion, and autophagy
inhibition in glioblastoma cell lines. Biology (Basel).
10:4672021.PubMed/NCBI
|
|
130
|
Yang W, Liu Y, Gao R, Yu H and Sun T:
HDAC6 inhibition induces glioma stem cells differentiation and
enhances cellular radiation sensitivity through the SHH/Gli1
signaling pathway. Cancer Lett. 415:164–176. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Clement V, Sanchez P, de Tribolet N,
Radovanovic I and Ruiz i Altaba A: Hedgehog-GLI1 signaling
regulates human glioma growth, cancer stem cell self-renewal, and
tumorigenicity. Curr Biol. 17:165–172. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Balbous A, Renoux B, Cortes U, Milin S,
Guilloteau K, Legigan T, Rivet P, Boissonnade O, Martin S, Tripiana
C, et al: Selective release of a cyclopamine glucuronide prodrug
toward stem-like cancer cell inhibition in glioblastoma. Mol Cancer
Ther. 13:2159–2169. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Bensalma S, Chadeneau C, Legigan T, Renoux
B, Gaillard A, de Boisvilliers M, Pinet-Charvet C, Papot S and
Muller JM: Evaluation of cytotoxic properties of a cyclopamine
glucuronide prodrug in rat glioblastoma cells and tumors. J Mol
Neurosci. 55:51–61. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Wang K, Chen D, Qian Z, Cui D, Gao L and
Lou M: Hedgehog/Gli1 signaling pathway regulates MGMT expression
and chemoresistance to temozolomide in human glioblastoma. Cancer
Cell Int. 17:1172017. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Carballo GB, Matias D, Ribeiro JH, Pessoa
LS, Arrais-Neto AM and Spohr TCLSE: Cyclopamine sensitizes
glioblastoma cells to temozolomide treatment through sonic Hedgehog
pathway. Life Sci. 257:1180272020. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Liu YJ, Ma YC, Zhang WJ, Yang ZZ, Liang
DS, Wu ZF and Qi XR: Combination therapy with micellarized
cyclopamine and temozolomide attenuate glioblastoma growth through
Gli1 down-regulation. Oncotarget. 8:42495–42509. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Chen J, Lv H, Hu J, Ji M, Xue N, Li C, Ma
S, Zhou Q, Lin B, Li Y, et al: CAT3, a novel agent for
medulloblastoma and glioblastoma treatment, inhibits tumor growth
by disrupting the Hedgehog signaling pathway. Cancer Lett.
381:391–403. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Ji M, Wang L, Chen J, Xue N, Wang C, Lai
F, Wang R, Yu S, Jin J and Chen X: CAT3, a prodrug of
13a(S)-3-hydroxyl-6,7-dimethoxyphenanthro[9,10-b]-indolizidine,
circumvents temozolomide-resistant glioblastoma via the Hedgehog
signaling pathway, independently of O6-methylguanine DNA
methyltransferase expression. Onco Targets Ther. 11:3671–3684.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Horrigan SK; Reproducibility Project, :
Cancer Biology: Replication study: The CD47-signal regulatory
protein alpha (SIRPa) interaction is a therapeutic target for human
solid tumors. Elife. 6:e181732017. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
von Roemeling CA, Wang Y, Qie Y, Yuan H,
Zhao H, Liu X, Yang Z, Yang M, Deng W, Bruno KA, et al: Therapeutic
modulation of phagocytosis in glioblastoma can activate both innate
and adaptive antitumour immunity. Nat Commun. 11:15082020.
View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Chakrabarti J, Holokai L, Syu L, Steele
NG, Chang J, Wang J, Ahmed S, Dlugosz A and Zavros Y: Hedgehog
signaling induces PD-L1 expression and tumor cell proliferation in
gastric cancer. Oncotarget. 9. 37439-37457; 2018, View Article : Google Scholar
|
|
142
|
Grund-Gröschke S, Stockmaier G and Aberger
F: Hedgehog/GLI signaling in tumor immunity-new therapeutic
opportunities and clinical implications. Cell Commun Signal.
17:1722019. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
SurveillanceEpidemiology, End Results
Program, . Cancer stat facts: Brain and other nervous system
cancer. 2019.https://seer.cancer.gov/statfacts/html/brain.htmlJuly
12–2019
|
|
144
|
Braun S, Oppermann H, Mueller A, Renner C,
Hovhannisyan A, Baran-Schmidt R, Gebhardt R, Hipkiss A, Thiery J,
Meixensberger J and Gaunitz F: Hedgehog signaling in glioblastoma
multiforme. Cancer Biol Ther. 13:487–495. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Filbin MG, Dabral SK, Pazyra-Murphy MF,
Ramkissoon S, Kung AL, Pak E, Chung J, Theisen MA, Sun Y,
Franchetti Y, et al: Coordinate activation of Shh and PI3K
signaling in PTEN-deficient glioblastoma: New therapeutic
opportunities. Nat Med. 19:1518–1523. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Lan X, Jörg DJ, Cavalli FMG, Richards LM,
Nguyen LV, Vanner RJ, Guilhamon P, Lee L, Kushida MM, Pellacani D,
et al: Fate mapping of human glioblastoma reveals an invariant stem
cell hierarchy. Nature. 549:227–232. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Han S, Zhang C, Li Q, Dong J, Liu Y, Huang
Y, Jiang T and Wu A: Tumour-infiltrating CD4(+) and CD8(+)
lymphocytes as predictors of clinical outcome in glioma. Br J
Cancer. 110:2560–2568. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Heimberger AB, Abou-Ghazal M, Reina-Ortiz
C, Yang DS, Sun W, Qiao W, Hiraoka N and Fuller GN: Incidence and
prognostic impact of FoxP3+ regulatory T cells in human gliomas.
Clin Cancer Res. 14:5166–5172. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Wainwright DA, Chang AL, Dey M,
Balyasnikova IV, Kim CK, Tobias A, Cheng Y, Kim JW, Qiao J, Zhang
L, et al: Durable therapeutic efficacy utilizing combinatorial
blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.
Clin Cancer Res. 20:5290–5301. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Heimberger AB, Sun W, Hussain SF, Dey M,
Crutcher L, Aldape K, Gilbert M, Hassenbusch SJ, Sawaya R,
Schmittling B, et al: Immunological responses in a patient with
glioblastoma multiforme treated with sequential courses of
temozolomide and immunotherapy: Case study. Neuro Oncol. 10:98–103.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Jackson CM, Choi J and Lim M: Mechanisms
of immunotherapy resistance: Lessons from glioblastoma. Nat
Immunol. 20:1100–1109. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Sampson JH, Gunn MD, Fecci PE and Ashley
DM: Brain immunology and immunotherapy in brain tumours. Nat Rev
Cancer. 20:12–25. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Reardon DA, Brandes AA, Omuro A,
Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bähr
O, et al: Effect of nivolumab vs bevacizumab in patients with
recurrent glioblastoma: The CheckMate 143 phase 3 randomized
clinical trial. JAMA Oncol. 6:1003–1010. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Chiocca EA, Nassiri F, Wang J, Peruzzi P
and Zadeh G: Viral and other therapies for recurrent glioblastoma:
Is a 24-month durable response unusual? Neuro Oncol. 21:14–25.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Iorgulescu JB, Reardon DA, Chiocca EA and
Wu CJ: Immunotherapy for glioblastoma: Going viral. Nat Med.
24:1094–1096. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Brown CE, Alizadeh D, Starr R, Weng L,
Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J,
Simpson J, et al: Regression of glioblastoma after chimeric antigen
receptor T-cell therapy. N Engl J Med. 375:2561–2569. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Lassman A, Pugh S, Wang T, Aldape K, Gan
H, Preusser M, Vogelbaum M, Sulman E, Won M, Zhang P, et al:
ACTR-21. A randomized, double-blind, placebo-controlled phase 3
trial of depatuxizumab mafodotin (ABT-414) in epidermal growth
factor receptor (EGFR) amplified (AMP) newly diagnosed glioblastoma
(nGBM). Neuro Oncol. 21 (Suppl 6):vi172019. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Ma DJ, Galanis E, Anderson SK, Schiff D,
Kaufmann TJ, Peller PJ, Giannini C, Brown PD, Uhm JH, McGraw S, et
al: A phase II trial of everolimus, temozolomide, and radiotherapy
in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro
Oncol. 17:1261–1269. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Wick W, Gorlia T, Bady P, Platten M, van
den Bent MJ, Taphoorn MJ, Steuve J, Brandes AA, Hamou MF, Wick A,
et al: Phase II study of radiotherapy and temsirolimus versus
radiochemotherapy with temozolomide in patients with newly
diagnosed glioblastoma without MGMT promoter hypermethylation
(EORTC 26082). Clin Cancer Res. 22:4797–4806. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Lombardi G, De Salvo GL, Brandes AA, Eoli
M, Rudà R, Faedi M, Lolli I, Pace A, Daniele B, Pasqualetti F, et
al: Regorafenib compared with lomustine in patients with relapsed
glioblastoma (REGOMA): A multicentre, open-label, randomised,
controlled, phase 2 trial. Lancet Oncol. 20:110–119. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Kim EJ, Sahai V, Abel EV, Griffith KA,
Greenson JK, Takebe N, Khan GN, Blau JL, Craig R, Balis UG, et al:
Pilot clinical trial of Hedgehog pathway inhibitor GDC-0449
(vismodegib) in combination with gemcitabine in patients with
metastatic pancreatic adenocarcinoma. Clin Cancer Res.
20:5937–5945. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Berlin J, Bendell JC, Hart LL, Firdaus I,
Gore I, Hermann RC, Mulcahy MF, Zalupski MM, Mackey HM, Yauch RL,
et al: A randomized phase II trial of vismodegib versus placebo
with FOLFOX or FOLFIRI and bevacizumab in patients with previously
untreated metastatic colorectal cancer. Clin Cancer Res.
19:258–267. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Belani CP, Dahlberg SE, Rudin CM, Fleisher
M, Chen HX, Takebe N, Velasco MR Jr, Tester WJ, Sturtz K, Hann CL,
et al: Vismodegib or cixutumumab in combination with standard
chemotherapy for patients with extensive-stage small cell lung
cancer: A trial of the ECOG-ACRIN cancer research group (E1508).
Cancer. 122:2371–2378. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Zubčić V, Rinčić N, Kurtović M, Trnski D,
Musani V, Ozretić P, Levanat S, Leović D and Sabol M: GANT61 and
lithium chloride inhibit the growth of head and neck cancer cell
lines through the regulation of GLI3 processing by GSK3β. Int J Mol
Sci. 21:64102020. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Miyazaki Y, Matsubara S, Ding Q, Tsukasa
K, Yoshimitsu M, Kosai K and Takao S: Efficient elimination of
pancreatic cancer stem cells by Hedgehog/GLI inhibitor GANT61 in
combination with mTOR inhibition. Mol Cancer. 15:492016. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Pietrobono S, Gagliardi S and Stecca B:
Non-canonical Hedgehog signaling pathway in cancer: Activation of
GLI transcription factors beyond smoothened. Front Genet.
10:5562019. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Kim J, Lee JJ, Kim J, Gardner D and Beachy
PA: Arsenic antagonizes the Hedgehog pathway by preventing ciliary
accumulation and reducing stability of the Gli2 transcriptional
effector. Proc Natl Acad Sci USA. 107:13432–13437. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Yanai K, Nakamura M, Akiyoshi T, Nagai S,
Wada J, Koga K, Noshiro H, Nagai E, Tsuneyoshi M, Tanaka M and
Katano M: Crosstalk of Hedgehog and Wnt pathways in gastric cancer.
Cancer Lett. 263:145–156. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Nanta R, Shrivastava A, Sharma J, Shankar
S and Srivastava RK: Inhibition of sonic Hedgehog and PI3K/Akt/mTOR
pathways cooperate in suppressing survival, self-renewal and
tumorigenic potential of glioblastoma-initiating cells. Mol Cell
Biochem. 454:11–23. 2019. View Article : Google Scholar : PubMed/NCBI
|
